Loading...

Sonoma Pharmaceuticals, Inc.

SNOANASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$3.94
$0.74(23.12%)

Sonoma Pharmaceuticals, Inc. (SNOA) Stock Overview

Explore Sonoma Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.9/100

Key Financials

Market Cap6.4M
P/E Ratio-1.41
EPS (TTM)$-2.79
ROE-0.71%
Fundamental Analysis

AI Price Forecasts

1 Week$3.50
1 Month$5.25
3 Months$5.62
1 Year Target$1.99

SNOA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sonoma Pharmaceuticals, Inc. (SNOA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 76.21, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.99.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.41 and a market capitalization of 6.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

76.21RSI (14)
0.05MACD
26.99ADX
Revenue Growth
-4.05%
4.05%
Profit Growth
$-2.79
6.13%
EPS Growth
$-2.79
64.95%
Operating Margin
-25.97%
2.87%
ROE
-70.52%
6.13%
Dividend Yield
0.00%
Analyst Recommendations data is not available for SNOAAnalyst Recommendations details for SNOA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

CEO

Amy M. Trombly

Employees

10

Headquarters

645 Molly Lane, Woodstock, GA

Founded

2007

Frequently Asked Questions

;